Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)

Conclusions: BID is a well-tolerated and effective combination therapy for pts. with heavily treated RRMM. Planned maintenance therapy was not used in this study and might be effective for prolonging responses.DisclosuresDhakal: Celgene: Consultancy, Honoraria; Takeda: Honoraria, Research Funding; Amgen: Honoraria. D'Souza: Celgene: Research Funding; Merck: Research Funding; Prothena: Consultancy, Research Funding; Takeda: Research Funding; Amgen: Research Funding. Hamadani: Merck: Research Funding; Sanofi Genzyme: Research Funding, Speakers Bureau; ADC Therapeutics: Research Funding; MedImmune: Consultancy, Research Funding; Ostuka: Research Funding; Celgene Corporation: Consultancy; Cellerant: Consultancy; Takeda: Research Funding; Janssen: Consultancy. Shah: Miltenyi: Other: Travel funding, Research Funding; Geron: Equity Ownership; Exelexis: Equity Ownership; Juno Pharmaceuticals: Honoraria; Oncosec: Equity Ownership; Lentigen Technology: Research Funding. Hari: Celgene: Consultancy, Honoraria, Research Funding; Amgen Inc.: Research Funding; Spectrum: Consultancy, Research Funding; Kite Pharma: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Janssen: Honoraria; Sanofi: Honoraria, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Dhakal, B., D'Souza, A., Hamadani, M., Arce-Lara, C. E., Schroeder, K., Chhabra, S., Shah, N. N., Gauger, K., Keaton, T., Pasquini, M. C., Hari, P. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research